Cadrenal Therapeutics, Inc. Common Stock (CVKD) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cadrenal Therapeutics, Inc. Common Stock (CVKD) has a cash flow conversion efficiency ratio of -1.671x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.00 Million) by net assets ($1.80 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See CVKD equity to assets ratio to measure how much of total assets are equity-financed.
Cadrenal Therapeutics, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2022–2025)
This chart illustrates how Cadrenal Therapeutics, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check CVKD total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
Cadrenal Therapeutics, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cadrenal Therapeutics, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Flour Mills Kepenos S.A.
AT:KEPEN
|
0.322x |
|
Magna Terra Minerals Inc
V:MTT
|
-0.282x |
|
Ornapaper Bhd
KLSE:5065
|
0.032x |
|
Thunderful Group AB
ST:THUNDR
|
-0.023x |
|
DeepMarkit Corp.
NASDAQ:MKTSF
|
0.168x |
|
Sarytogan Graphite Ltd
AU:SGA
|
0.039x |
|
Glen Burnie Bancorp
NASDAQ:GLBZ
|
0.020x |
|
Cyclerion Therapeutics Inc
NASDAQ:CYCN
|
-0.173x |
Annual Cash Flow Conversion Efficiency for Cadrenal Therapeutics, Inc. Common Stock (2022–2025)
The table below shows the annual cash flow conversion efficiency of Cadrenal Therapeutics, Inc. Common Stock from 2022 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Cadrenal Therapeutics, Inc. Common Stock.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $2.74 Million | $-12.60 Million | -4.601x | -365.26% |
| 2024-12-31 | $7.44 Million | $-7.36 Million | -0.989x | -115.49% |
| 2023-12-31 | $7.69 Million | $-3.53 Million | -0.459x | -311.46% |
| 2022-12-31 | $-5.55 Million | $-1.20 Million | 0.217x | -- |
About Cadrenal Therapeutics, Inc. Common Stock
Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company focuses on developing therapeutics for rare cardiovascular conditions. The company is developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with… Read more